Ascorbic Acid Market

Future Market Insights suggests that within the ascorbic acid landscape, the divestiture of dsm-firmenich's commodity-grade Chinese production (DSM Jiangshan sale) alongside its retention of the premium Quali-C Dalry, Scotland facility, the acquisition-driven peptide-integration strategy of Northeast Pharmaceutical Group, and the Chinese producer shift toward value-over-volume pricing in Q1 2026 are creating a structural bifurcation between commodity-grade and pharmaceutical/cosmetic-grade ascorbic acid supply chains. Analysts identify the dsm-firmenich portfolio restructuring and the Chinese price stabilisation pivot as the central pivot points for the industry, effectively splitting global supply into a high-volume Chinese commodity tier and a Western premium-certified tier serving pharma, cosmetics, and nutraceutical applications.